Biomet Not IPO Friendly

Biomet (No stock symbol) announced improved results and looked every bit the take over or IPO candidate. They announced that knew replacements and hip replacements are up in almost every part of the world. The presentation is not investor friendly. You need to be an insider in the industry to understand the underlying dynamics of why hip replacement sales are doing better in one market than another. If the investor is to be engaged Biomet will need to talk in terms of markets, regulatory overviews and competing offerings. At the present time they do neither.

Disclosure: No position in any stocks mentioned in this post.